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Abstract
Background: We hypothesized that a substantial proportion of the subjectively experienced
variance in pain in fibromyalgia patients would be explained by psychological factors alone, but that
a combined model, including neuroendocrine and autonomic factors, would give the most
parsimonious explanation of variance in pain.
Methods:  Psychometric assessment included McGill Pain Questionnaire, General Health
Questionnaire, Hospital Anxiety and Depression Rating Scale, Eysenck personality Inventory,
Neuroticism and Lie subscales, Toronto Alexithymia Scale, and Multidimensional Health Locus of
Control Scale and was performed in 42 female patients with fibromyalgia and 48 female age
matched random sample population controls. A subgroup of the original sample (22 fibromyalgia
patients and 13 controls) underwent a pharmacological challenge test with buspirone to assess
autonomic and adrenocortical reactivity to serotonergic challenge.
Results: Although fibromyalgia patients scored high on neuroticism, anxiety, depression and
general distress, only a minor part of variance in pain was explained by psychological factors alone.
High pain score was associated with high neuroticism, low baseline cortisol level and small drop in
systolic blood pressure after buspirone challenge test. This model explained 41.5% of total pain in
fibromyalgia patients. In population controls, psychological factors alone were significant predictors
for variance in pain.
Conclusion: Fibromyalgia patients may have reduced reactivity in the central sympathetic system
or perturbations in the sympathetic-parasympathetic balance. This study shows that a
biopsychosocial model, including psychological factors as well as factors related to perturbations of
the autonomic nervous system and hypothalamic-pituitary-adrenal axis, is needed to explain
perceived pain in fibromyalgia patients.
Background
Fibromyalgia is a chronic pain syndrome with steadily
fluctuating musculo-skeletal pain as the main symptom.
However, despite intensive research, the primary mecha-
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nisms underlying the etiopathogenesis of fibromyalgia re-
main elusive.
Some psychiatric studies suggest a relationship to anxiety
disorder in a significant subgroup [1,2], while other stud-
ies have found that fibromyalgia is highly associated with
depressive disorders [3–7]. Many psychometric studies in-
dicate an association between fibromyalgia, chronic dis-
tress, anxiety, depression and certain personality traits [8–
15], although conflicting results exist [16,17].
During the last decade many authors have suggested that
perturbations in the autonomic nervous system is a key el-
ement in the fibromyalgia syndrome, however, contradic-
tory results have been reported [18–23]. Also
perturbations of the hypothalamic-pituitary-adrenal
(HPA) axis, leading to relative insufficiency of the adrenal
glands and hypocortisolism, is a neuroendocrine finding
that has been described in fibromyalgia patients [24–26].
Stress, either physical, emotional or metabolic in nature,
may be the essential underlying factor leading to psychiat-
ric and somatic symptoms in fibromyalgia patients
through a final common pathway [27]. The physiology of
stress includes CNS and peripheral components, involv-
ing the hypothalamic-pituitary-adrenal (HPA) axis, the
hypothalamic-pituitary-gonadal (HPG) axis and the auto-
nomic (sympathetic) system.[28,29]. Stress, leading to
perturbations in all these systems, may elicit pain in fibro-
myalgia patients [30].
Although a vast literature concerning etiopathogenetic
factors in the fibromyalgia syndrome exists, we have
found no published studies focusing upon which of all
these factors that are most important to explain the ever
changing and troublesome pain in these patients. This is a
clinical important and meaningful question, as knowl-
edge about factors influencing variance in pain is essential
in the search for more efficacious pain treatment for fibro-
myalgia patients. To clarify this question, we assessed
pain, psychiatric symptoms and personality factors in pa-
tients with fibromyalgia and population based controls.
We also used a psychopharmacological challenge test to
assess autonomic and adrenocortical cortisol responsive-
ness. We hypothesized that a substantial proportion of the
subjectively experienced variance in pain in fibromyalgia
patients would be explained by psychological factors
alone, but that a combined model also including neu-
roendocrine and autonomic factors as a base of the symp-





Caucasian female fibromyalgia patients fulfilling the ACR
diagnostic criteria for fibromyalgia [31] were randomly
selected from the Outpatient clinic of the Rheumatologi-
cal department, Haukeland University Hospital. Forty-
two female patients with mean age 44 years (range 29–63)
were included.
The control group was population-based and consisted of
age-matched Caucasian women living in the city of Ber-
gen recruited from the National Register by a randomised
computer procedure. Mean age for the 48 controls was 46
years (range 23–68).
Sample II
All subjects not using any psychoactive, anti-inflammato-
ry or antihistaminic drugs on daily basis who were includ-
ed sample I, were invited to take part in the further study.
Twenty-two women with fibromyalgia (mean age 45
years, range 29–63), and 14 female controls (mean age 43
years, range 30–65) accepted and were included.
General assessment
All subjects underwent a detailed and comprehensive clin-
ical physical examination with registration of demograph-
ic and general medical data. No significant group
differences were found in age or total family monthly in-
come. Fibromyalgia patients had on average 11 years of
education, while control subjects had 13 years (p= 0.018).
Pain assessment
Pain was assessed by the Norwegian version of the MPQ
[32]. The Norwegian version has three main scales: senso-
ric pain, affective pain and evaluative pain. Sensoric pain
is defined as the sum score of 12 subscales on different
sensoric aspects of pain. Affective pain is the sum score of
the 5 word groups describing affective aspects of pain.
One word group gives the score for evaluative pain. Total
pain is the sum score of sensoric, affective and evaluative
pain. One fibromyalgia patient and one control did not
complete the questionnaire.
Psychometric assessment
The patients filled in a package of questionnaires. General
Health Questionnaire 30-item version (GHQ-30) assesses
the presence of distress and overall well-being [33]. Sum
score was calculated by the Likert method (0-1-2-3). Hos-
pital Anxiety and Depression scale (HAD-A and HAD-D)
is constructed to measure psychological (psychic) symp-
toms of anxiety and depression in a medically ill popula-
tion [34].BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/12
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The neuroticism scale of the Eysenck Personality Ques-
tionnaire (EPQ-N) assesses general tendency to over-re-
sponsiveness or over-reactivity (neuroticism) [35]. The
typical high EPQ-N scorer is an anxious, worrying individ-
ual, moody and frequently depressed. She is likely to sleep
badly, and to suffer from various psychosomatic disor-
ders. High EPQ-N-scores have been reported among pa-
tients with fibromyalgia. The lie scale of the Eysenck
Personality Questionnaire (EPQ-L) assesses a tendency to-
wards social conformity and a tendency to give only the
answers the person supposes are "correct". Very high
scores may be associated with actual lying.
Alexithymia was measured by the 26-item version of To-
ronto Alexithymia Scale (TAS) [36]. Alexithymia is a mul-
tidimensional construct defined by a difficulty in
identifying and describing feelings, a difficulty in distin-
guishing between feelings and bodily sensations, a pauci-
ty of fantasies and a preoccupation with external events.
Alexithymia has been proposed to increase the risk for
functional syndromes.
Multi Dimensional Health Locus of Control Scale
(MHLCS) is an ordinal scale with three subscales of 6
items each (scoring 0–6). MHLCS measures how the sub-
jects evaluated the possibility to have control of their own
health [37]. The Internal control score is a measure of the
individuals' own perceived control of their health. Chance
score measures a tendency to perceive health as an out-
come of luck or fate. External control score is a measure of
the individuals' tendency to expect outcome to be directed
by powerful others. In general terms, internal locus of
control has been found to predict better coping.
Buspirone challenge test
A buspirone challenge test was performed to assess auto-
nomic and adrenocortical responsiveness in the subjects.
Buspirone is a well-known and safe azapiron, which pro-
duces a fall in blood pressure. This effect is at least partly
due to inhibition of sympathoexcitatory neurons located
in the rostral ventrolateral medulla [38]. However, bus-
pirone may also decreases blood pressure through mech-
anisms associated with parasympathetic activation).)[39].
In addition, buspirone induces plasma adrenocortico-
tropic hormone (ACTH) and cortisol release [40].
All the premenopausal women were tested within the first
two weeks of the menstrual cycle, i.e. in the follicular
phase. Buspirone tests began at 8.30 a.m. after an over-
night fast. A venous cannula was inserted, and after 15
minutes rest a blood sample was taken for baseline deter-
minations of plasma cortisol. At 9 a.m. 60 mg of oral bus-
pirone in special pharmacy-prepared gelatine-containing
capsules was administered. Blood pressure and venous
samples were drawn after 60, 90, and 150 minutes. The
time points were selected after a review of the literature
which showed these time points to be the most adequate
for measurement of blood pressure and hormonal re-
sponses to buspirone [41–43]. The subjects rested semi-
supine throughout the blood-sampling period and were
not allowed to sleep.
Venous samples were taken into tubes and centrifuged
within 4 hours. Plasma was stored at -80°C until assay.
Statistical analysis
The statistical analyses were conducted by the SPSS-PC
statistical package, version 9.0 (SPSS 1999). Mean differ-
ences in variables were assessed by one-way analyses of
variance. Correlation analyses were performed between
pain variables and psychological and variables derived
from the buspirone challenge test. Linear regression anal-
yses with stepwise backward procedures were performed
to find the model giving the most parsimonious explana-
tion of the variance in pain. In the large sample, all psy-
chological variables were entered into the regression
analysis. Psychological factors that contributed signifi-
cantly to explained variance in pain in fibromyalgia pa-
tients, were entered together with buspirone challenge test
variables in the regression analysis from the limited sam-
ple.
Ethics
All subjects were thoroughly informed by personal in-
struction and a written informed consent was obtained at
inclusion. The Regional ethics committee and The Norwe-
gian Data Inspectorate accepted the study. The study was
performed in accordance with the Helsinki declaration.
Results
Pain
As expected, fibromyalgia patients had higher scores than
controls on all pain scales (Table 1). Scores for sensoric,
affective and evaluative pain were significantly inter-corre-
lated in both groups with correlation coefficients between
0.41 and 0.91.
Psychological variables
Fibromyalgia patients scored higher than controls on anx-
iety (HAD-A), depression (HAD-D), general distress
(GHQ-30) and neuroticism (EPQ-N). The MHLCS factor
"Chance" was higher, and "Internal" was lower in the pa-
tient group than in the control group (Table 2).
As expected, psychological symptom scores on HAD-A,
HAD-D and GHQ were highly inter-correlated (r > 0.60, p
< 0.001) and correlated also highly (r > 0.50, p < 0.01)
with EPQ-N and alexithymia (TAS) scores in both groups.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/12
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In fibromyalgia patients, sensoric, affective and total pain
correlated significantly with EPQ-N (r = 0.31 - 0.34, p =
0.03 - 0.05), and affective pain correlated significantly
with TAS (r = 0.32, p = 0.04). In controls, sensoric, affec-
tive and total pain scores correlated positively with HAD-
A (r = 0.30, p = 0.03), HAD-D (r = 0.44, p = 0.002), GHQ
(r = 0.46, p = 0.001), EPQ-N (r = 0.40, p = 0.004) and neg-
atively with MHLCS "Internal"(r = -0.45, p = 0.002).
Buspirone test
No significant group differences were seen in baseline cor-
tisol level or in baseline systolic or diastolic blood pres-
sure. Buspirone produced a significant time-dependent
increase in plasma cortisol and a significant fall in systolic
and diastolic blood pressure with no significant group dif-
ferences. In fibromyalgia patients, high pain scores (sen-
soric, affective and total) were significantly correlated
with low baseline cortisol (Table 3). A consistent pattern
of negative correlations between pain scores and cortisol
response to buspirone was also seen. These correlations
did not reach statistical significance however (rmax = -
0.37, p = 0.09). Pain scores were also significantly corre-
lated with drop in systolic and diastolic blood pressure
(high pain, low drop in blood pressure, Table 3). In con-
trols, affective pain score was significantly correlated (r = -
0.56, p = 0.04) with drop in systolic, but not diastolic,
blood pressure after buspirone. However, on the contrary
to what was found in fibromyalgia patients, high affective
pain score was associated with a large drop in systolic
blood pressure.
Predictors of pain
In the total sample, only a small proportion of variance in
pain could be explained by variables related to personality
and psychological symptoms in the 42 fibromyalgia pa-
tients. The best model consisted of the variables EPQ-N
and EPQ-L, which explained 0% of the variance in evalu-
ative pain, 12.6% of variance in affective pain, 13.5% of
variance in sensoric pain and 15.7% of variance in total
pain.
Table 1: Pain in female patients with fibromyalgia and female population controls: mean scores and 95% confidence intervals
Mc Gill Pain Questionnaire Fibromyalgia N = 42 Controls N = 48 ANOVA F-value Probability p*
Evaluative pain 4.7 (3.8–5.5) 2.5 (1.7–3.2) 15.26 <0.001
Affective pain 19.1 (16.1–22.1) 7.3 (4.3–10.4) 30–73 <0.001
Sensoric pain 38.7 (33.0–44.3) 17.2 (11.8–22.6) 30.50 <0.001
Total pain 62.4 (54.0–70.8) 27.0 (18.4–35.6) 34.61 <0.001
Table 2: Psychological variables in female patients with fibromyalgia and female population controls: mean scores with 95% confidence 
intervals
Fibromyalgia (N = 42) Controls (N = 48) ANOVA F-value P-value
Psychological symptoms
HAD-A 6.2 (5.0–7.4) 4.4 (3.5–5.4) 5.4 0.02
HAD-D 4.9 (3.7–6.0) 2.3 (1.5–3.0) 15.5 <0.001
GHQ-30 likert 33.6 (29–28) 24.1 (21–27) 14.2 <0.001
Personality
EPQ-N 10.1 (8.5–11.6) 7.6 (6.1–9.0) 5.5 0.02
EPQ-L 9.9 (8.7–11.0) 9.6 (8.7–10.4) 0.2 0.69
TAS 67.7 (65–71) 64.9 (62–68) 1.6 0.21
MHLC
Internal 20.2 (18.5–22.0) 23.8 (22.2–25.3) 9.0 0.004
Chance 16.4 (14.8–18.0) 13.9 (12.6–15.2) 6.2 0.02
External 15.4 (13.7–17.1) 16.0 (15.0–17.4) 0.3 0.60
EPQ-N: Eysenck personality Questionnaire, Neuroticism scale, EPQ-L: Eysenck Personality Questionnaire, Lie scale, TAS: Toronto Alexithymia 
Scale, MHLCS: Multidimensional Health Locus of Control Scale, HAD-A and HAD-D: Hospital Anxiety and Depression Scale, GHQ: General 
Health Questionnaire, F1: Defensive hostility, F2: Instrumental mastery-oriented Coping, F3: Cognitive defence, F4: Emotional focused copingBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/12
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A larger proportion of variance in pain was explained by
psychological variables in the 48 control subjects. A mod-
el consisting of the variables Internal and Chance health
locus of control and total GHQ score explained 21.6% of
variance in evaluative pain, 32.6% of variance in affective
pain, 28.0% of variance in sensoric pain and 32.5% of var-
iance in total pain.
In the subjects who also performed the buspirone test, a
model consisting of EPQ-N, baseline cortisol level and
change in systolic blood pressure explained 41.5% of total
pain in fibromyalgia patients. High pain score was associ-
ated with high EPQ-N, low baseline cortisol level and
small drop in systolic blood pressure after buspirone chal-
lenge test (Table 4). In controls, EPQ-N was the only sig-
nificant predictor for variance in sensoric- and total pain.
Discussion
The main finding in this study is that a biopsychosocial
model including psychological factors as well as factors re-
lated to perturbation of the autonomic nervous system
and the HPA-axis explained a substantial part of variance
of pain in the fibromyalgia patients.
When only personality factors and psychological distress
was taken into account, we found a more limited impact
of personality factors and psychological distress on pain
severity than what has been reported in some previous
studies [8,9,44,45]. A possible explanation for this could
be that our fibromyalgia group consisted of extreme cases
with high scores on psychopathology and pain with small
inter-individual differences. However, this did not seem
to be case. Even though there were significant differences
in mean scores between patients and controls for some of
the psychological variables, the mean scores in the fibro-
myalgia group correspond more to "moderately high nor-
mal scores " than to scores from a psychiatrically ill
population.
Some authors have claimed that the personality trait alex-
ithymia, "no words for feelings" are common in fibromy-
algia patients [46,47]. This was not confirmed in our
study, as no differences were seen in alexithymia scores.
However, a high correlation was found between alex-
ithymia scores and scores for anxiety, depression and neu-
roticism, which may indicate that alexithymia scores may
be associated with psychological distress. Also previous
studies have showed a strong association between alex-
ithymia and depression and a general lack of absolute sta-
bility for the construct).)[48,49].
Fibromyalgia patients scored moderately lower on inter-
nal health locus of control and higher on chance health
locus of control than control subjects. The cognitive inter-
pretation of this pattern could be something like: "What-
ever I do, my illness just go on". The same pattern has
been identified as being associated with reduced likeli-
hood for engaging in healthy behaviour in young adults
[50], but could in our opinion also be interpreted as an ef-
fect of chronic illness in the fibromyalgia patient sample.
The most powerful predictor for increased sensoric pain in
fibromyalgia patients was a reduced drop in systolic blood
pressure after buspirone challenge. One possible explana-
tion for this finding is that fibromyalgia patients display
perturbations in central sympathetic system with reduced
reactivity, which might be due to reduced sensitivity of 5-
HT1A receptors on sympathoexcitatory neurons in the ros-
tral ventrolateral medulla. However, perturbations in the
sympathetic-parasympathetic balance in fibromyalgia pa-
tients could also explain the results.
Our finding corresponds to previous findings suggesting
alterations in autonomic regulation in fibromyalgia pa-
tients. Neuropeptide Y, which co-exists with norepine-
phrine in the sympathetic nervous system and may
represent the sympathetic-neuronal output, has been
found to be elevated in fibromyalgia patients [18]. Also al-
tered modulation of the sympathetic nervous system with
deranged sympathetic response to orthostatic stress has
previously been found in this patient group [21,22].
Studies have provided convincing evidence that the adre-
nal gland is hypoactive in some stress-related states as
posttraumatic stress disorder, in healthy individuals living
under conditions of chronic stress as well as in patients
with several bodily disorders including chronic fatigue
Table 3: Correlations between buspirone challenge test variables 




Controls        
(N = 13)




Baseline cortisol -0.43* (p = 0.04) 0.15 (p = 0.61)
∆  Cortisol -0.31 (p = 0.15) 0.37 (p = 0.22)
Baseline systolic blood pressure -0.33 (p = 0.14) 0.43 (p = 0.13)
∆  Systolic blood pressure 0.50* (p = 0.02) -0.31 (p = 0.28)
Baseline diastolic blood pres-
sure
-0.26 (p = 0.24) 0.28 (p = 0.33)
∆  Diastolic blood pressure 0.50* (p = 0.02) 0.00 (p = 1.00)
∆  = Level after 90 minutes-baseline level High pain scores are associ-
ated with a small drop in blood pressure (∆  systolic blood pressure) 
after buspirone in fibromyalgia patients. A smaller drop in blood pres-
sure after buspirone gives a smaller negative ∆  value, and hence the 
seen positive correlation.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/12
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syndrome, fibromyalgia, other somatoform disorders,
rheumatoid arthritis, and asthma [24,25,51]. It has been
hypothesized that a persistent lack of cortisol availability
in traumatized or chronically stressed individuals may
promote an increased vulnerability for the development
of stress-related bodily disorders [51].
Our results partly confirm these previous results. Al-
though there were no mean differences in baseline corti-
sol between fibromyalgia patients and control subjects, a
negative association was found between pain and baseline
cortisol. A trend was seen in the regression analysis be-
tween a small cortisol response to buspirone challenge
and increased pain, but the cortisol responsiveness to ser-
otonergic challenge only explained a minor and nonsig-
n i f i c a n t  p a r t  o f  v a r i a n c e  i n  p a i n .  H o w e v e r ,  o u r
methodology does not allow us to assess the relative im-
portance of sympathetic dysregulation and relative adre-
nal insufficiency as cortisol and blood pressure responses
to buspirone may not be truly independent variables. Cor-
ticosteroids may influence sympathetic neuronal excita-
bility, and activity in the sympatho-adrenal system may
influence cortisol secretion [52,53].
In controls, a different pattern was seen than in fibromy-
algia patients. Psychological distress was strongly associat-
ed with perceived pain, and only affective pain was found
to be associated with autonomic reactivity. Our finding of
a correlation between high drop in blood pressure and
high affective pain may indicate an association between
affective pain and high sympathetic reactivity in popula-
tion controls. However, the small sample size implicates
cautiousness in the interpretation of the results.
Some methodological weaknesses are present in this
study. Pain and other symptoms in fibromyalgia patients
may vary through the menstrual cycle [54]. However, we
were not able to control for this in our study. Buspirone
has multiple pharmacological actions and may not be an
ideal drug for pharmacological challenge, but was chosen
because of its previous frequent use and known safety in
human neuroendocrine studies. It is recognized that the
first pass effect is extensive, and the major metabolite 1-(-
2 pyrimdinyl) piperazine (1-PP) acts as a α 2 adrenoceptor
antagonist. This may interfere with the interpretation of
the results on a receptor level, but it has no impact on our
main conclusions. In this study we were not able to meas-
ure plasma levels of buspirone or its metabolites, and
Table 4: Explained variance in pain by (backward) regression analysis in femalepatients with fibromyalgia and female controls
Fibromyalgia (N = 22) Controls (N = 13)
Pain Model Adj. r2 t-score p-value Adj. r2 t-score p-value
Evaluative Model 0.00 0.00
Affective Model 0.38 0.014
EPQ-N 2.69 0.015
Baseline cortisol -2.72 0.014
∆  systBT 2.04 0.057 0.36 2.76 0.019
Sensoric Model 0.47 0.004
EPQ-N 2.32 0.033 0.49 3.59 0.004
Baseline cortisol -2.56 0.020
∆  cortisol -1.74 0.099
∆  systBT 3.00 0.008
Total Model 0.42 0.005
EPQ-N 2.36 0.030 0.36 7.68 0.018
Baseline cortisol -2.68 0.015
∆  systBT 2.79 0.012
Adj. r2: adjusted r2, ∆  systBT: systolic blood pressure after 90 minutes – baseline systolic blood pressure, ∆  cortisol: cortisol level after 90 minutes 
– baseline cortisolBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/12
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pharmacokinetic differences due to for instance differenc-
es in absorption between groups cannot be excluded. The
relatively small sample size may also have lead to type two
errors.
Conclusions
This study confirms that a biopsychosocial model is need-
ed to explain variance in pain in fibromyalgia patients.
Personality traits related to over-reactivity or over-respon-
siveness (neuroticism) and social conformity as well as
factors related to perturbation of the autonomic nervous
system and the HPA-axis explained a substantial part of
variance of pain in the fibromyalgia patients. Neuroticism
and psychological distress also were good predictors of
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